公开(公告)号：US20180105516A1

公开(公告)日：2018-04-19

申请号：US15847407

申请日：2017-12-19

Applicant: Genentech, Inc.

Inventor： Benjamin FAUBER ,  Emanuela GANCIA ,  Tammy LADDUWAHETTY ,  David VESEY ,  Paul WINSHIP ,  Olivier RENE

IPC: C07D417/14 ,  A61P17/06 ,  C07D417/10

CPC classification number: C07D417/14 ,  A61K31/541 ,  A61P17/06 ,  A61P19/02 ,  C07D417/10 ,  C07D417/12

Abstract: Compounds of the formula I: or pharmaceutically acceptable salts thereof, wherein m, n, p, q, r, X1, X2, X3, X4, Y, Z, A, Het, R1, R2, R3, R4, R5 R6, R7, R8, R9, R10, R11, R12 and R13 are as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of inflammatory diseases such as arthritis, muscular sclerosis and psoriasis.

公开(公告)号：US20210299110A1

公开(公告)日：2021-09-30

申请号：US17178021

申请日：2021-02-17

Applicant: Genentech, Inc.

Inventor： Timothy HEFFRON ,  Sushant MALHOTRA ,  BinQing WEI ,  Bryan CHAN ,  Lewis GAZZARD ,  Emanuela GANCIA ,  Michael LAINCHBURY ,  Andrew MADIN ,  Eileen SEWARD ,  Yonghan HU

IPC: A61K31/437 ,  A61K31/444 ,  A61K31/506 ,  A61K31/513 ,  A61K31/5377 ,  C07D471/04

Abstract: Azaindole compounds and their use as inhibitors of HPK1 are described. The compounds are useful in treating HPK1-dependent disorders and enhancing an immune response. Also described are methods of inhibiting HPK1, methods of treating HPK1-dependent disorders, methods for enhancing an immune response, and methods for preparing the azaindole compounds.

公开(公告)号：US20200000780A1

公开(公告)日：2020-01-02

申请号：US16568459

申请日：2019-09-12

Applicant: Genentech, Inc.

Inventor： Timothy HEFFRON ,  Sushant MALHOTRA ,  BinQing WEI ,  Bryan CHAN ,  Lewis GAZZARD ,  Emanuela GANCIA ,  Michael LAINCHBURY ,  Andrew MADIN ,  Eileen SEWARD ,  Yonghan HU

IPC: A61K31/437 ,  A61K31/444 ,  A61K31/5377 ,  C07D471/04 ,  A61K31/506 ,  A61K31/513

Abstract: Azaindole compounds and their use as inhibitors of HPK1 are described. The compounds are useful in treating HPK1-dependent disorders and enhancing an immune response. Also described are methods of inhibiting HPK1, methods of treating HPK1-dependent disorders, methods for enhancing an immune response, and methods for preparing the azaindole compounds.